Skip to main content

Arq Reports Fourth Quarter and Full Year 2025 Results

Generated record revenue of approximately $120 million for full-year 2025, driven by PAC performance Reported Adjusted EBITDA(1) of $13 million, representing 26% improvement year-over-year Provided inaugural financial guidance for full-year 2026 Pausing GAC production and development to conduct comprehensive engineering and production process optimization review Announced leadership changes, including appointment of industry veteran as VP Operations and Finance team reorganization GREENWOOD VILLAGE, Colo., March 09, 2026 (GLOBE NEWSWIRE) — Arq, Inc. (NASDAQ: ARQ) (the “Company” or “Arq”), a producer of activated carbon and other environmentally efficient carbon products for use in purification and sustainable materials, today announced its financial and operating results for the quarter and year ended December 31,...

Continue reading

Flagship Communities Real Estate Investment Trust Announces Fourth Quarter and Full Year 2025 Results

Not for distribution to U.S. newswire services or dissemination in the United States. TORONTO, March 09, 2026 (GLOBE NEWSWIRE) — Flagship Communities Real Estate Investment Trust (“Flagship” or the “REIT”) (TSX: MHC.U; MHC.UN) today released its fourth quarter and full year 2025 results. The financial results of the REIT have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). Results are shown in U.S. dollars, unless otherwise noted. Fourth Quarter 2025 ResultsCompared to Fourth Quarter 2024 ResultsRental revenue and related income was $27.5 million, an increase of 15.6% compared to $23.8 million Same Community Revenue1 was $23.2 million, up 8.2% compared to $21.4 million Net income and comprehensive income was $45.5 million...

Continue reading

SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027 Reported Phase 1 clinical data, including healthy volunteer, redosing, and T1D cohorts supporting SAB-142’s favorable safety profile, redosability, and continued clinical development Raised $175 million in an oversubscribed private placement with leading institutional and strategic investors to fully fund SAFEGUARD Strong cash position with operational runway through 2028 MIAMI, March 09, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced financial...

Continue reading

Alaris Releases 2025 Fourth Quarter Financial Results

Not for Distribution in the United States. Failure to Comply With This Restriction May Constitute a Violation of United States Securities Law. CALGARY, Alberta, March 09, 2026 (GLOBE NEWSWIRE) — Alaris Equity Partners Income Trust (together, as applicable, with its subsidiaries, “Alaris” or the “Trust“) is pleased to announce its results for the three months and year ended December 31, 2025. The results are prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board. All amounts below are in Canadian dollars unless otherwise noted. HighlightsStrong Operating Growth: Total revenue and operating income increased 15.9% in Q4 and 14.0% for the year, driven primarily by a $73.2 million net unrealized gain on Partner investments (2024 – $47.3 million). Earnings from operations...

Continue reading

NL REPORTS FOURTH QUARTER 2025 RESULTS

Dallas, Texas, March 09, 2026 (GLOBE NEWSWIRE) — NL Industries, Inc. (NYSE: NL) today reported a net loss attributable to NL stockholders of $31.0 million, or $.63 per share, in the fourth quarter of 2025 compared to net income attributable to NL stockholders of $16.5 million, or $.34 per share, in the fourth quarter of 2024. NL’s results include an unrealized loss of $4.5 million in the fourth quarter of 2025 compared to an unrealized loss $12.0 million in the fourth quarter of 2024 related to the change in value of marketable equity securities. For the full year of 2025, NL reported a net loss attributable to NL stockholders of $37.8 million, or $.77 per share, compared to net income attributable to NL stockholders of $67.2 million, or $1.38 per share for the full year of 2024. NL’s full year results include an unrealized loss...

Continue reading

Greenlight Re Announces Financial Results for Fourth Quarter and Year-End December 31, 2025

Improves Q4 Combined Ratio to 92.1%, Achieves Record Full-Year Underwriting Income. GRAND CAYMAN, Cayman Islands, March 09, 2026 (GLOBE NEWSWIRE) — Greenlight Capital Re, Ltd. (NASDAQ: GLRE) (“Greenlight Re” or the “Company”) today reported its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 Highlights (all comparisons are to fourth quarter 2024 unless noted otherwise):Gross premiums written increased 12% to $161.3 million; Net premiums earned increased 12% to $165.6 million; Net underwriting income of $13.0 million, compared to an underwriting loss of $18.0 million; Combined ratio of 92.1%, compared to 112.1%; Total investment income of $44.8 million, compared to $2.6 million; Net income of $49.3 million, or $1.44 per diluted ordinary share, compared to a net loss of $27.4 million,...

Continue reading

KRONOS WORLDWIDE, INC. REPORTS FOURTH QUARTER 2025 RESULTS

Dallas, Texas, March 09, 2026 (GLOBE NEWSWIRE) — Kronos Worldwide, Inc. (NYSE:KRO) today reported a net loss of $82.8 million, or $.72 per share, in the fourth quarter of 2025 compared to a net loss of $13.2 million, or $.12 per share, in the fourth quarter of 2024. For the full year of 2025, Kronos Worldwide reported a net loss of $110.9 million, or $.96 per share, compared to net income of $86.2 million, or $.75 per share, for the full year of 2024. Our net loss increased in the fourth quarter of 2025 compared to the fourth quarter of 2024 due to lower income from operations primarily due to higher unabsorbed fixed production costs resulting from production curtailments and lower average TiO2 selling prices somewhat offset by higher sales volumes. In addition, we recorded non-cash deferred income tax expense of $8.5 million ($.07...

Continue reading

FreightCar America, Inc. Reports Fourth Quarter and Full Year 2025 Results

Strong full year gross profit growth and over 260 basis points of gross margin expansion despite challenging industry environment Operating cash flow of $35 million and Adjusted Free Cash Flow of $31 million, up 45% year over year Projecting growth in 2026 CHICAGO, March 09, 2026 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer and supplier of railroad freight cars, railcar parts and components, today reported results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 HighlightsRevenues of $125.6 million, compared to $137.7 million in the fourth quarter of 2024, with railcar deliveries of 1,172 units compared to 1,019 units in the prior year period Gross margin of 13.4% with gross profit of $16.8 million, compared to...

Continue reading

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 million in year ending cash, cash equivalents and marketable securities – – Conference call today at 4:30 p.m. Eastern Standard Time – REDWOOD CITY, Calif., March 09, 2026 (GLOBE NEWSWIRE) — Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the full year and fourth quarter 2025, and provided an overview of recent business highlights. “We are pleased with our progress in 2025, having doubled LOQTORZI sales while completing the transformation from a biosimilars company to an innovative oncology company focused on overcoming immune resistance in cancer. At the same time, we continued to reduce our overall...

Continue reading

Fluent Announces Unaudited Fourth Quarter and Full-Year 2025 Financial Results; Commerce Media Solutions Revenue Run Rate Exceeds $105 Million and Represents 56% of Consolidated Enterprise Revenue

Revenue of $61.8 million for Q4 2025 and $208.8 million for FY 2025Q4 2025 Commerce Media Solutions revenue grew 101% to $34.7 million (56% of consolidated revenue) from $17.2 million (26% of revenue) in Q4 2024 with gross profit margin (exclusive of depreciation and amortization) of 33% in Q4 2025 compared to 30% for the consolidated businessCommerce Media Solutions annual revenue run rate now exceeds $105 million, with media margin of 30% reflecting a sequential improvement of $20 million and five basis points, respectively, compared to Q3 2025Expect double-digit revenue growth on aggregate continuing business and adjusted EBITDA improvement for full year 2026NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a commerce media solutions company, today reported unaudited results for the fourth quarter...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.